(XNCR) Xencor - Ratings and Ratios
Monoclonal Antibodies, Bispecific Antibodies, Cancer Therapies
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 62.9% |
| Value at Risk 5%th | 92.2% |
| Relative Tail Risk | -10.82% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.36 |
| Alpha | -55.99 |
| CAGR/Max DD | -0.32 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.519 |
| Beta | 1.392 |
| Beta Downside | 1.009 |
| Drawdowns 3y | |
|---|---|
| Max DD | 81.06% |
| Mean DD | 48.04% |
| Median DD | 46.40% |
Description: XNCR Xencor December 26, 2025
Xencor, Inc. (NASDAQ: XNCR) is a clinical-stage biopharma that engineers monoclonal antibodies for asthma, allergic, autoimmune diseases and oncology. Its marketed products include Ultomiris (atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica), Monjuvi (relapsed/refractory diffuse large B-cell lymphoma) and Sotrovimab (SARS-CoV-2). The pipeline features a range of XmAb bispecific antibodies-XmAb819 (renal cell carcinoma), XmAb541 (ovarian cancer), Vudalimab (metastatic castration-resistant prostate cancer), XmAb564 (autoimmune), and several early-stage candidates targeting solid tumors, inflammatory bowel disease, HIV, hepatitis Delta, Alzheimer’s, and other indications.
As of the latest 10-K, Xencor reported FY 2023 revenue of approximately $85 million, driven primarily by royalty and collaboration payments, and held a cash runway of roughly $300 million, giving it > 12 months of liquidity at current burn. The company’s partnership with Novartis on the XmAb Fc platform and a 2022 licensing deal with J&J for a bispecific oncology program together contribute an estimated $250 million in upfront and milestone payments, underscoring the market’s appetite for engineered antibody technologies. The broader biotech sector continues to benefit from a 7-year compound annual growth rate (CAGR) of ~ 12 % in antibody therapeutics, while FDA’s accelerated approval pathways keep timelines compressed for high-need indications.
For a deeper quantitative view of Xencor’s valuation metrics and peer comparison, you may find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -138.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.17 > 0.02 and ΔFCF/TA -2.48 > 1.0 |
| NWC/Revenue: 258.1% < 20% (prev 473.2%; Δ -215.1% < -1%) |
| CFO/TA -0.16 > 3% & CFO -139.0m > Net Income -138.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.99 > 1.5 & < 3 |
| Outstanding Shares: last quarter (74.4m) vs 12m ago 16.23% < -2% |
| Gross Margin: 64.74% > 18% (prev 0.88%; Δ 6387 % > 0.5%) |
| Asset Turnover: 18.07% > 50% (prev 10.34%; Δ 7.73% > 0%) |
| Interest Coverage Ratio: -1.36 > 6 (EBITDA TTM -68.6m / Interest Expense TTM 58.5m) |
Altman Z'' -3.67
| A: 0.50 (Total Current Assets 518.4m - Total Current Liabilities 86.5m) / Total Assets 868.8m |
| B: -0.91 (Retained Earnings -789.3m / Total Assets 868.8m) |
| C: -0.09 (EBIT TTM -79.5m / Avg Total Assets 926.2m) |
| D: -3.23 (Book Value of Equity -787.4m / Total Liabilities 243.5m) |
| Altman-Z'' Score: -3.67= D |
Beneish M -2.03
| DSRI: 1.30 (Receivables 21.8m/10.2m, Revenue 167.4m/101.7m) |
| GMI: 1.36 (GM 64.74% / 87.87%) |
| AQI: 0.94 (AQ_t 0.30 / AQ_t-1 0.31) |
| SGI: 1.65 (Revenue 167.4m / 101.7m) |
| TATA: 0.00 (NI -138.7m - CFO -139.0m) / TA 868.8m) |
| Beneish M-Score: -2.03 = BB |
ValueRay F-Score (Strict, 0-100) 18.01
| 1. Piotroski: 1.0pt |
| 2. FCF Yield: -22.29% |
| 3. FCF Margin: -85.85% |
| 4. Debt/Equity: 0.32 |
| 5. Debt/Ebitda: data missing |
| 6. ROIC - WACC: -18.79% |
| 7. RoE: -21.65% |
| 8. Revenue Trend: -34.31% |
| 9. EPS Trend: -7.23% |
What is the price of XNCR shares?
Over the past week, the price has changed by -0.76%, over one month by -17.91%, over three months by -1.35% and over the past year by -36.57%.
Is XNCR a buy, sell or hold?
- Strong Buy: 8
- Buy: 3
- Hold: 0
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the XNCR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 28.8 | 119.9% |
| Analysts Target Price | 28.8 | 119.9% |
| ValueRay Target Price | 10.5 | -19.8% |
XNCR Fundamental Data Overview January 19, 2026
P/B = 1.4606
Revenue TTM = 167.4m USD
EBIT TTM = -79.5m USD
EBITDA TTM = -68.6m USD
Long Term Debt = 115.2m USD (from longTermDebt, last fiscal year)
Short Term Debt = 49.3m USD (from shortTermDebt, last quarter)
Debt = 202.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 174.1m USD (from netDebt column, last quarter)
Enterprise Value = 644.7m USD (913.3m + Debt 202.4m - CCE 471.0m)
Interest Coverage Ratio = -1.36 (Ebit TTM -79.5m / Interest Expense TTM 58.5m)
EV/FCF = -4.49x (Enterprise Value 644.7m / FCF TTM -143.7m)
FCF Yield = -22.29% (FCF TTM -143.7m / Enterprise Value 644.7m)
FCF Margin = -85.85% (FCF TTM -143.7m / Revenue TTM 167.4m)
Net Margin = -82.91% (Net Income TTM -138.7m / Revenue TTM 167.4m)
Gross Margin = 64.74% ((Revenue TTM 167.4m - Cost of Revenue TTM 59.0m) / Revenue TTM)
Gross Margin QoQ = 87.62% (prev 93.92%)
Tobins Q-Ratio = 0.74 (Enterprise Value 644.7m / Total Assets 868.8m)
Interest Expense / Debt = 3.79% (Interest Expense 7.67m / Debt 202.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -62.8m (EBIT -79.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.99 (Total Current Assets 518.4m / Total Current Liabilities 86.5m)
Debt / Equity = 0.32 (Debt 202.4m / totalStockholderEquity, last quarter 625.3m)
Debt / EBITDA = -2.54 (negative EBITDA) (Net Debt 174.1m / EBITDA -68.6m)
Debt / FCF = -1.21 (negative FCF - burning cash) (Net Debt 174.1m / FCF TTM -143.7m)
Total Stockholder Equity = 640.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -14.98% (Net Income -138.7m / Total Assets 868.8m)
RoE = -21.65% (Net Income TTM -138.7m / Total Stockholder Equity 640.8m)
RoCE = -10.52% (EBIT -79.5m / Capital Employed (Equity 640.8m + L.T.Debt 115.2m))
RoIC = -9.21% (negative operating profit) (NOPAT -62.8m / Invested Capital 681.7m)
WACC = 9.58% (E(913.3m)/V(1.12b) * Re(11.04%) + D(202.4m)/V(1.12b) * Rd(3.79%) * (1-Tc(0.21)))
Discount Rate = 11.04% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 10.59%
Fair Price DCF = unknown (Cash Flow -143.7m)
EPS Correlation: -7.23 | EPS CAGR: -7.45% | SUE: 1.88 | # QB: 3
Revenue Correlation: -34.31 | Revenue CAGR: -41.22% | SUE: -0.33 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.63 | Chg30d=-0.004 | Revisions Net=+0 | Analysts=8
EPS next Year (2026-12-31): EPS=-2.62 | Chg30d=+0.019 | Revisions Net=+3 | Growth EPS=-43.5% | Growth Revenue=-3.4%
Additional Sources for XNCR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle